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Abstract
The kidney is a relatively infrequent site for solitary fibrous tumor (SFT). Among the previously reported cases, only
two cases of malignant renal SFT developing via dedifferentiation from a pre-existing benign SFT have been
reported. Here we reported a case of de novo malignant renal SFT clinically diagnosed as renal cell carcinoma in a
50-year-old woman. The tumor was circumscribed but unencapsulated and showed obvious hemorrhagic necrosis.
Microscopically, the tumor was composed of patternless sheets of alternating hypercellular and hypocellular areas
of spindle cells displaying mild to moderate nuclear atypia, frequent mitoses up to 8 per 10 high power fields, and
a 20% Ki-67 proliferative index. Immunohistochemical studies revealed reactivity for CD34, CD99 and vimentin, with
no staining for all other markers, confirming the diagnosis of SFT. No areas of dedifferentiation were seen after
extensive sampling. Based on the pathologic and immunohistochemical features, a diagnosis of de novo malignant
renal SFT was warranted. Our report expands the spectrum of malignant progression in renal SFTs. Even though
this patient has been disease-free for 30 months, long-term follow-up is still mandatory.
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Backround
Solitary fibrous tumors (SFTs) are distinctive mesenchy-
mal tumors most commonly described as pleural-based
lesions; however they can develop at any extrapleural
anatomic site [1]. Although the clinical course of SFTs is
rather unpredictable, the prognosis of SFTs is generally
favorable. It is estimated that 10% to 15% of intrathoracic
SFTs and up to 10% of extrathoracic SFTs will recur and/
or metastasize [2,3], therefore SFT is regarded as an
“intermediate malignant, rarely metastasizing” neoplasm
[4]. Microscopic features associated with malignancy in
both intrathoracic and extrathoracic SFTs include
nuclear atypia, increased cellularity and more than 4
mitoses per 10 high power fields [4,5]. An additional fac-
tor conferring a worse prognosis in SFTs is dedifferentia-
tion or sarcomatous overgrowth, which represents an
abrupt transition to a morphologically anaplastic compo-
nent [6]. The kidney is a relatively infrequent site for
SFT, with at least 36 cases reported in a review article
[7]. The vast majority of renal SFTs are histologically
benign and only two cases of malignant renal SFTs devel-
oping via dedifferentiation or sarcomatous overgrowth
from a pre-existing benign SFT have been reported [7,8].
Here we report the first case of de novo malignant renal
SFT without dedifferentiation and thus expand the spec-
trum of malignant progression in renal SFTs.
Case presentation
Clinical summary
A 50-year-old woman was admitted to our hospital with
one-month history of soreness and pain in her right flank,
without gross hematuria or other constitutional symp-
toms. Laboratory findings were unremarkable. Physical
examination revealed a palpable right flank mass. A com-
puted topography (CT) of the abdomen showed a huge
necrotic tumor occupying the perirenal space of right kid-
ney without evidence of either local invasion or lymphade-
nopathy (Figure 1). The patient underwent right radical
nephrectomy under a pre-operative diagnosis of American
Joint Committee on Cancer (AJCC) stage II (T2aN0) renal
cell carcinoma. Post-operation course was smooth.
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Pathologic findings
A nephrectomy specimen (15 × 9 × 7 cm, 670 g) with
attached ureter and perirenal fibroadipose tissue was
received. The specimen was bisected to reveal a 9 × 9 ×
6 cm circumscribed but unencapsulated tumor occupy-
ing the perirenal space of the upper and middle poles of
kidney. The tumor was firm and showed a yellowish
white to tan-gray, myxoid and lobulated cut surface
with prominent hemorrhage and necrosis (Figure 2).
Microscopically, the tumor showed proliferation of spin-
dle cells arranging in a patternless architecture (Figure
3A) with a combination of alternating hypercellular and
hypocellular areas (Figure 3B). Haphazard, storiform, or
short fascicular arrangements of spindle cells in a loose
myxoid to fibrous stroma containing dense collagen
fibers were also seen (Figure 3C). Dilated and branching
hemangiopericytoma-like vessels were frequently
observed (Figure 3D). Tumor cells had plump, fusiform,
or elongated hyperchromatic nuclei with mild to moder-
ate pleomorphism and indistinct cell borders and
frequent mitoses up to 8 per 10 high power fields.
Abnormal mitoses were occasionally seen (Figure 3E).
Tumor necrosis was evidently present (Figure 3F). We
did not find any areas of dedifferentiation after extensive
tumor sampling.
Immunohistochemically, the tumor showed weak
CD34 positivity (Figure 4A) and diffusely strong CD99
(Figure 4B) and vimentin staining. They stained nega-
tively for bcl-2 protein, S-100 protein, NSE, muscle mar-
kers, cytokeratin, CD117(C-kit), p53 and HMB-45. Ki-67
immunostaining, analyzed by ImmuoRatio quantitative
i m a g es o f t w a r e[ 9 ] ,s h o w e da2 0 %p r o l i f e r a t i v ei n d e x .
The immunohistochemical findings were highly consis-
tent with SFT. Based on the microscopic features
including increased cellularity, cellular atypia, frequent
mitoses, a high proliferative index, necrosis and absence
of dedifferentiation, a diagnosis of de novo malignant
solitary fibrous tumor was established.
Discussion
SFT is a relatively uncommon but distinctive mesenchy-
mal neoplasm, originally described in the pleura cavity
and later reported to occur ubiquitously [1]. Although
Figure 1 CT of the abdomen. Arterial phase images of dynamic
computed topography scan showed a highly necrotic tumor
compressing the renal parenchyma without either invasion to
surrounding tissues or local lymphadenopathy.
Figure 2 Gross morphology. The tumor was firm and showed a yellowish white to tan-gray, myxoid and lobulated cut surface with prominent
hemorrhage and necrosis in the center.
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studies strongly favor a primitive mesenchymal or peri-
vascular cell origin [10]. The kidney is a relatively infre-
quent site for SFT, with approximately at least 36 cases
of renal SFT reported in a review article [7]. Clinically,
these cases were frequently considered to be malignant
due to their large tumor size by physical examinations
and radiographic studies. Symptoms do not differ from
those reported by patients with renal cell carcinoma.
Hypoglycemia, which is a rare symptom in intrathoracic
and extrathoracic SFTs, was not reported in any renal
SFTs including our case [2].
Malignant behaviors in the form of recurrence and/or
metastases can occur in 10% to 15% of intrathoracic
SFTs and up to 10% of extrathoracic SFTs [2,3]. Malig-
nant SFT is postulated to develop via two pathways: (1)
de novo occurrence or (2) dedifferentiation or sarcoma-
tous overgrowth from a pre-exsisting histologically
benign SFT [1,4]. Most renal SFTs were classified as his-
tologically benign and showed a favorable prognosis, with
no evidence of recurrence during a follow-up period ran-
ging from 2 to 89 months [7]. To our knowledge, two
cases of malignant renal SFTs developing via dedifferen-
tiation or sarcomatous overgrowth from a pre-existing
Figure 3 Photomicrographs. A, Proliferation of spindle cells arranging in a patternless architecture (×200 original magnification). B, Alternating
hypercellular and hypocellular areas of spindle cells separated from each other by bands of collagen fiber (×200 original magnification). C,
Spindle cells forming haphazard, storiform, or short fascicular arrangements in a loose myxoid to fibrous stroma containing dense collagen fibers
(×200 original magnification). D, Hemangiopericytoma-like staghorn-like vessels (×200 original magnification). E, Tumor cells displaying mild to
moderate atypia and 3 mitoses in this high power field (arrow and arrowhead) (×400 original magnification). Abnormal mitoses were
occasionally seen (inset, ×400 original magnification). F, Prominent tumor necrosis (× 400 original magnification).
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et al., respecvievely [7,8]. A detailed comparison of the
clinicopatholgoic features of these two cases and ours is
summarized in Table 1. The tumor reported by Fine et
al. had infiltrative borders and focal necrosis, and invaded
beyond the renal capsule. The tumor described by Margo
et al. was a 9-cm circumscribed mass devoid of either
hemorrhage or necrosis. Notably, there was a 3-cm nodu-
lar area within the main tumor, microscopically respond-
ing to sarcomatous overgrowth. In contrast, our tumor
showed a homogeneous cut surface with prominent
necrosis and hemorrhage. Microscopically, the tumor
reported by Fine et al. and Margo et al. showed typical
features of benign SFT with 90% and 30% of dedifferen-
tiation or sarcomatous overgrowth, respectively. In con-
trast, our tumor appeared to develop de novo since we
did not find any areas of dedifferentiation after extensive
tumor sampling.
The criteria for clinical malignancy in intrathoracic
SFT, first proposed by England et al. in 1989, include
increased cellularity, pleomorphism, mitotic count more
than 4 per 10 high power fields, necrosis, hemorrhage,
size more than 10 cm, non-pedunculated and atypical
locations (parietal pleura, pulmonary parenchyma) [5].
T h ed i a g n o s t i cc r i t e r i af o rm a l i g n a n te x t r a t h o r a c i cS F T s
are purely microscopic and include increased cellularity,
pleomorphism and mitotic count more than 4 per 10
high power fields [4,11]. Currently the impact of tumor
characteristics (size, hemorrhage, necrosis and location)
in predicting clinical malignancy in extrathoracic SFTs
remains to be investigated. Our case fulfilled the diagnos-
tic criteria for malignant extrathoracic SFTs. Addition-
ally, the presence of hemorrhage and necrosis and a 20%
Ki-67 proliferative index further supports a diagnosis of
malignant renal SFT.
SFTs show a wide variety of microscopic growth pat-
terns and should be distinguished from benign and
malignant spindle cell tumors. Positive immunoreactivity
for CD34 and CD99 is characteristic of SFT, and highly
valuable in differentiating from other mesenchymal
tumors [2,4]. However the expression of CD34 and
CD99 may be decreased or absent in areas with marked
atypia or dedifferentiation [8,12]. Genetic analyses of
SFT to date have not found consistent and characteristic
cytogenetic abnormalities that can be used an ancillary
diagnostic marker. Missense mutation of platelet-derived
growth factor receptor-b (PDGFR-b) has been reported
in 2 of 88 pleuro-pulmonary SFTs [13], but we did not
detect PDGFR-b mutation in our case (data not shown).
The prognosis of extrapleural SFTs is more unpredict-
able than that of pleural tumors due to lack of large-
scale studies. The clinical outcomes were rather strik-
ingly different in the two malignant renal SFTs with
dedifferentiation. While a patient developed multiple
small lung nodules 4 months post-operatively [8], the
other patient was disease-free after 15 months of follow-
up [7]. Our patient has been well without evidence of
recurrence or metastasis for 30 months. Some studies
Figure 4 Immunohistochemical photomicrographs.
Immunohistochemicaly, the tumor cells showing A, Weak to
moderate CD34 immunostaining (×200 original magnification). B,
Strong and diffuse CD99 immunostaining (×200 original
magnification). C, Ki-67 immunostaining, analyzed by ImmuoRatio
quantitative image software, showing a 20% proliferative index
(×400 original magnification).
Hsieh et al. Diagnostic Pathology 2011, 6:96
http://www.diagnosticpathology.org/content/6/1/96
Page 4 of 6indicated that extrapleural SFTs had similar prognosis as
the pleural counterpart, and a tumor with malignant
histological feature was associated with recurrence and
metastasis [3,14], but other studies showed that extra-
pleural SFTs tended to have a favorable outcome than
pleural ones, even those with malignant histological fea-
tures [11,15]. Studies also showed that deep-seated loca-
tions, over-expression of p53 and p16, loss of CD34
immunostaining and the presence of dedifferentiated
areas may indicate more aggressive behaviors [6]. Com-
plete surgical excision and long-term follow-up are gen-
erally recommended for patients with extrapleural SFTs
[15]. Besides, due to the rich vascularity and possible
origin from pericytes, antiangiogenic therapy, especially
for the advanced cases is also under clinical investiga-
tion [16].
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